Evidence map›Paper›PMID 27936091›Full record

ArticlePloS one2016

Development of Serum Marker Models to Increase Diagnostic Accuracy of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: The New LINKI Algorithm Compared with Established Algorithms.

Byron Lykiardopoulos, Hannes Hagström, Mats Fredrikson, Simone Ignatova, Per Stål, Rolf Hultcrantz, Mattias Ekstedt, Stergios Kechagias

Open access · goldAbstract readComparative Study
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Repeated measurements of non-invasive fibrosis tests to monitor the progression of non-alcoholic fatty liver disease: A long-term follow-up study.Liver international : official journal of the International Association for the Study of the Liver · 2022
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Byron LykiardopoulosDepartment of Medical and Health Sciences, Linköping University, Linköping, Sweden.
Hannes HagströmDepartment of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden.
Mats FredriksonDepartment of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.
Simone IgnatovaDepartment of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.
Per StålDepartment of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden.
Rolf HultcrantzDepartment of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden.
Mattias EkstedtDepartment of Medical and Health Sciences, Linköping University, Linköping, Sweden.
Stergios KechagiasDepartment of Medical and Health Sciences, Linköping University, Linköping, Sweden.ORCID http://orcid.org/0000-0001-7614-739X
Linköping University · SEKarolinska Institutet · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimDetection of advanced fibrosis (F3-F4) in nonalcoholic fatty liver disease (NAFLD) is important for ascertaining prognosis. Serum markers have been proposed as alternatives to biopsy. We attempted to develop a novel algorithm for detection of advanced fibrosis based on a more efficient combination of serological markers and to compare this with established algorithms.

methodsWe included 158 patients with biopsy-proven NAFLD. Of these, 38 had advanced fibrosis. The following fibrosis algorithms were calculated: NAFLD fibrosis score, BARD, NIKEI, NASH-CRN regression score, APRI, FIB-4, King´s score, GUCI, Lok index, Forns score, and ELF. Study population was randomly divided in a training and a validation group. A multiple logistic regression analysis using bootstrapping methods was applied to the training group. Among many variables analyzed age, fasting glucose, hyaluronic acid and AST were included, and a model (LINKI-1) for predicting advanced fibrosis was created. Moreover, these variables were combined with platelet count in a mathematical way exaggerating the opposing effects, and alternative models (LINKI-2) were also created. Models were compared using area under the receiver operator characteristic curves (AUROC).

resultsOf established algorithms FIB-4 and King´s score had the best diagnostic accuracy with AUROCs 0.84 and 0.83, respectively. Higher accuracy was achieved with the novel LINKI algorithms. AUROCs in the total cohort for LINKI-1 was 0.91 and for LINKI-2 models 0.89.

conclusionThe LINKI algorithms for detection of advanced fibrosis in NAFLD showed better accuracy than established algorithms and should be validated in further studies including larger cohorts.

Indexed as

AdultAgedAged, 80 and overAge FactorsAlanine TransaminaseAlgorithmsArea Under CurveAspartate AminotransferasesBiomarkersBlood GlucoseFemaleHumansLiverLiver CirrhosisLogistic ModelsMaleAlanine TransaminaseAspartate AminotransferasesBiomarkersBlood Glucose

Identifiers

PMID27936091
PMCPMC5147971
OpenAlexW2560234253

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.